Merck : MRK

All Merck Articles

1067 Articles

Paul Ausick | Jan 19, 2017 at 4:01 PM EST

Exxon Mobil, Merck Weigh on DJIA Thursday

Exxon Mobil, Merck, Goldman Sachs, and Pfizer sink the DJIA on Thursday.

Paul Ausick | Jan 14, 2017 at 10:15 AM EST

Merck Is Best Performing DJIA Stock So Far in 2017

Oddly, perhaps, the best performing stock in the first two weeks of the year is drug maker Merck.

Jon C. Ogg | Jan 12, 2017 at 1:20 PM EST

Why 3 Analysts Upgraded Merck Simultaneously

The the attacks against drug pricing and competition do not seem to be going away, but somehow, Merck has managed…

Chris Lange | Jan 12, 2017 at 10:50 AM EST

Major Pharma Short Interest Declines Ahead of Trump Comments

The short interest data have been released for the December 30 settlement date. Pharmaceutical companies usually are involved in a…

Jon C. Ogg | Jan 12, 2017 at 9:13 AM EST

Top Analyst Upgrades and Downgrades: AK Steel, Merck, Twitter, US Steel, Disney, Xerox and More

The the top analyst upgrades, downgrades and initiations on Thursday include AK Steel, Merck, Twitter, U.S. Steel, Walt Disney and…

Paul Ausick | Jan 11, 2017 at 4:01 PM EST

Merck, IBM Pace DJIA to Wednesday Gain

Merck, Intel, IBM, Goldman Sachs lead Dow Jones Industrial Average higher Wednesday.

Chris Lange | Jan 11, 2017 at 3:22 PM EST

Wednesday’s Top Biopharma Movers

Biotech and pharma companies were on the move Wednesday. A few of the smaller caps made tremendous gains on the…

Jon C. Ogg | Jan 10, 2017 at 7:45 AM EST

Forget 20,000: Why the 2017 DJIA Bull-Bear Outlook Points to 21,422

The DJIA bull-bear projection of 21,422 would be short of the preliminary look of 22,000 seen at the end of…

Lee Jackson | Jan 9, 2017 at 8:50 AM EST

Dogs of the Dow Could Be a Huge Winner Again in 2017

There is an investment vehicle that may offer investors a way to stay in equities, get paid solid dividends and…

Chris Lange | Jan 5, 2017 at 11:05 AM EST

2017 Bull-Bear Case for Health Care: J&J, Merck, Pfizer, UnitedHealth

Major Dow Jones Industrial Average companies in the health care sector saw a relatively strong 2016, with most posting a…

Paul Ausick | Jan 5, 2017 at 8:10 AM EST

How a Slimmer Procter & Gamble Might Fare in 2017

A slimmer portfolio is expected to pay off for Procter & Gamble investors as the company now focuses on 10…

Paul Ausick | Jan 3, 2017 at 4:01 PM EST

Nike, Verizon Lead DJIA Higher Tuesday

Thinkstock[cnxvideo id=”655424″ placement=”ros”]January 3, 2017: Markets opened higher Tuesday following the beginning of promised cuts to crude oil production by…

Jon C. Ogg | Dec 31, 2016 at 11:14 AM EST

Meet the 2017 Dogs of the Dow: Massive Dividends and Expected Upside

One strategy that has been quite common as investors rebalance and make changes each year is the Dogs of the…

Paul Ausick | Dec 28, 2016 at 4:01 PM EST

Caterpillar, Intel Sink DJIA Wednesday

December 28, 2016: Markets opened higher Wednesday but any recovery from Tuesday’s end-of-day selling failed to materialize. Trading reversed course…

Chris Lange | Dec 28, 2016 at 10:25 AM EST

Short Interest Rises in Major Pharma

The December 15 short interest data have been compared with the previous figures, and short interest increased in most of…

1 … 30 31 32 33 34 … 72

Merck : MRK

All Merck Articles

Exxon Mobil, Merck Weigh on DJIA Thursday

Merck Is Best Performing DJIA Stock So Far in 2017

Why 3 Analysts Upgraded Merck Simultaneously

Major Pharma Short Interest Declines Ahead of Trump Comments

Top Analyst Upgrades and Downgrades: AK Steel, Merck, Twitter, US Steel, Disney, Xerox and More

Merck, IBM Pace DJIA to Wednesday Gain

Wednesday’s Top Biopharma Movers

Forget 20,000: Why the 2017 DJIA Bull-Bear Outlook Points to 21,422

Dogs of the Dow Could Be a Huge Winner Again in 2017

2017 Bull-Bear Case for Health Care: J&J, Merck, Pfizer, UnitedHealth

How a Slimmer Procter & Gamble Might Fare in 2017

Nike, Verizon Lead DJIA Higher Tuesday

Meet the 2017 Dogs of the Dow: Massive Dividends and Expected Upside

Caterpillar, Intel Sink DJIA Wednesday

Short Interest Rises in Major Pharma

3 Biotech Stocks to Watch for Respectable Growth Beyond AI

Jill Schlesinger Greenlights $2.9M Retiree’s $200K Gift to Sons: ‘I Can’t Believe I’m Being the Dream Maker’

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Jill Schlesinger Greenlights $2.9M Retiree's $200K Gift to Sons: 'I Can't Believe I'm Being the Dream Maker'

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

3 Biotech Stocks to Watch for Respectable Growth Beyond AI

Jill Schlesinger Greenlights $2.9M Retiree’s $200K Gift to Sons: ‘I Can’t Believe I’m Being the Dream Maker’

Merck : MRK

All Merck Articles

Exxon Mobil, Merck Weigh on DJIA Thursday

Merck Is Best Performing DJIA Stock So Far in 2017

Why 3 Analysts Upgraded Merck Simultaneously

Major Pharma Short Interest Declines Ahead of Trump Comments

Top Analyst Upgrades and Downgrades: AK Steel, Merck, Twitter, US Steel, Disney, Xerox and More

Merck, IBM Pace DJIA to Wednesday Gain

Wednesday’s Top Biopharma Movers

Forget 20,000: Why the 2017 DJIA Bull-Bear Outlook Points to 21,422

Dogs of the Dow Could Be a Huge Winner Again in 2017

2017 Bull-Bear Case for Health Care: J&J, Merck, Pfizer, UnitedHealth

How a Slimmer Procter & Gamble Might Fare in 2017

Nike, Verizon Lead DJIA Higher Tuesday

Meet the 2017 Dogs of the Dow: Massive Dividends and Expected Upside

Caterpillar, Intel Sink DJIA Wednesday

Short Interest Rises in Major Pharma

3 Biotech Stocks to Watch for Respectable Growth Beyond AI

Jill Schlesinger Greenlights $2.9M Retiree’s $200K Gift to Sons: ‘I Can’t Believe I’m Being the Dream Maker’

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Featured Reads

Jill Schlesinger Greenlights $2.9M Retiree's $200K Gift to Sons: 'I Can't Believe I'm Being the Dream Maker'

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts